ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Antibodies"

  • 2017 American Transplant Congress

    De Novo Malignancy Occurrence After Kidney Transplantation in HLA-Sensitized Patients Treated with B-Cell Targeting Therapy.

    L. Couzi,1,2,3 P. Davis,1 J. Visentin,1,2,3 B. Taton,1 G. Guidicelli,1 H. Kaminski,1,2,3 P. Merville,1,2,3 T. Bachelet.4

    1CHU de Bordeaux, Bordeaux, France; 2Université de Bordeaux, Bordeaux, France; 3UMR CNRS 5164 Immunoconcept, Bordeaux, France; 4Clinique Saint-Augustin-CTMR, Bordeaux, France

    Management of high risk transplantations in patients with preformed DSA still remains a dilemma. Many groups propose to increase the immunosuppression in these patients by…
  • 2017 American Transplant Congress

    Impact of Immunosuppression Adherence on De Novo Donor-Specific Antibody Formation in Renal Transplant Recipients in Canada: A Modeling Analysis.

    J. Howell,1 R. Pollock,2 J. Schwartz.3

    1Astellas Pharma Global Development, Inc., Markham, ON, Canada; 2Ossian Health Economics and Communications GmbH, Basel, Switzerland; 3Astellas Pharma Global Development, Inc., Northbrook, IL

    Acute rejection rates and short-term graft survival have improved substantially as a result of advances in immunosuppression (IS), though longer-term graft survival rates have improved…
  • 2017 American Transplant Congress

    Anti-Angiotensin Type 1 Receptor Antibodies Associate with Rejection in Simultaneous Pancreas and Kidney Transplant and Pancreas Transplant Alone Recipients.

    A. Peng, D. Dafoe, J. Choi, A. Vo, X. Zhang, R. Najjar, E. Huang, S. Jordan.

    Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA

    Background: Anti-angiotensin type 1 receptor antibodies (AT1R Ab) have been found to have a strong association with antibody mediated rejection (Reinsmoen et al, Transpl 2010;…
  • 2017 American Transplant Congress

    Antibody-Mediated Vascular Rejection of Kidney Allografts: What Does It Happen After 15 Years?

    B. Rodriguez Cubillo,1 I. Perez Flores,1 M. Moreno De La Higuera,1 M. Calvo,1 N. Calvo Romero,1 A. Pascual,2 J. Cortes,2 J. Blanco,2 A. Sanchez-Fructuoso.1

    1Nephrology, Hospital Clínico San Carlos, Madrid, Spain; 2Histopathology, Hospital Clínico San Carlos, Madrid, Spain

    OBJECTIVE:To examine the association between subtypes of AVR and graft loss. We assessed patients who provided biopsy samples for acute allograft rejection, between 1998 and…
  • 2017 American Transplant Congress

    C3d Assay Result in Potential Transplant Recipients with HLA-DSA, AHG-CDC CxM Negative and FxM Positive or Negative with Their Potential Donors.

    A. Contreras, A. Casillas, N. Castelan, N. Gonzalez-Tableros, M. Lopez, A. Arvizu, A. De Santiago, J. Alberu, J. Arreola-Guerra.

    Transplantation Department, Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico

    Background: In a previous study we searched the association between the flow cytometry cross-match assay (FXM) result and the results obtained in the analysis of…
  • 2017 American Transplant Congress

    Distinctive Molecular Features of Antibody-Mediated versus T-Cell Mediated Rejection in Facial Transplantation.

    R. Lopdrup, T. Win, N. Murakami, J. Teague, A. Chandraker, G. Murphy, C. Lian, E. Bueno, B. Pomahac, R. Clark, L. Riella.

    Brigham and Women's Hospital, Boston, MA

    BackgroundA single case of antibody-mediated rejection in a clinical face transplant has been reported worldwide. The availability of repeated allograft biopsies from this patient allowed…
  • 2017 American Transplant Congress

    Prospective DSA Monitoring and Significance of De Novo DSA in Adult Liver Transplantation.

    S. Kubal,1 R. Mangus,1 J. Fridell,1 B. Ekser,1 R. Saxena,2 N. Rush,2 N. Higgins,4 M. Ghabril,3 M. Lacerda,3 A. Lobashevsky.4

    1Department of Surgery, Division of Transplantation, Indiana University School of Medicine, Indianapolis, IN; 2Department of Pathology, Indiana University School of Medicine, Indianapolis, IN; 3Department of Gastroenterology, Division of Hepatology, Indiana University School of Medicine, Indianapolis, IN; 4Department of Medicine, Immunology/Histocompatibility Laboratory, Indiana University School of Medicine, Indianapolis, IN

    Background: Post transplant course of circulating de novo donor specific antibodies (DSA) remains unknown after liver transplantation (LT).Methods: In a prospective study, sera from 92…
  • 2017 American Transplant Congress

    Long-Term Outcome of Antibody-Mediated Rejection Due to Pre-Existing vs. De Novo DSA in Kidney Allograft Recipients.

    O. Aubert,1 C. Lefaucheur,1 S. Higgins,1 L. Hidalgo,2 J. Duong Van Huyen,1 D. Viglietti,1 X. Jouven,1 D. Glotz,1 P. Halloran,2 A. Loupy.1

    1Paris Translational Research Center for Organ Transplantation, Paris, France; 2ATAGC, Edmonton, Canada

    BackgroundAntibody-mediated rejection (ABMR) can occur in patients with pre-existing anti-HLA donor-specific antibodies (DSA) or in patients who develop de novo DSA. However, how these processes…
  • 2017 American Transplant Congress

    Antibodies to Angiotensin Type II Receptor I Are Associated with Primary Graft Dysfunction After Orthotopic Heart Transplant in Patients with Ventricular Assist Device as Bridge to Transplant.

    M. Hickey,1 E. DePasquale,2 S. Shah,3 D. Vucicevic,2 J. Zhang,1 N. Valenzuela,1 M. Deng,2 E. Reed.1

    1UCLA Immunogenetics Center, Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA; 2UCLA Division of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA; 3UCLA David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA

    Primary graft dysfunction (PGD) following orthotopic heart transplant (OHT) is one of the leading causes of posttransplant mortality. We hypothesized that antibody to angiotensin type…
  • 2017 American Transplant Congress

    Chronic Antibody Mediated Rejection (cABMR) in ABO-Incompatible and ABO-Compatible Kidney Transplants: A Single US Center Experience.

    S. Sethi, A. Vo, E. Huang, L. Varanasi, J. Choi, A. Peng, R. Najjar, S. Jordan.

    Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA

    Introduction:Similar patient and graft outcomes have been previously reported for ABO compatible (ABOc) and ABO incompatible (ABOi) kidney transplants. However, data are limited on the…
  • « Previous Page
  • 1
  • …
  • 35
  • 36
  • 37
  • 38
  • 39
  • …
  • 57
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences